Pharmacopeia

Canonical comparison

Master Compare

Compare candidate-facing canonical Pharmacopeia fields side by side. Isolated AI-draft proposals are never included.

2selected

Field	ASPIRIN Haematology · Haematology · Level 2	ABCIXIMAB Haematology · Haematology · Level 3
Mechanism of action	Non-specific Irreversible platelet cyclooxygenase inhibitor (COX-1 and 2) via acetylation of serine residues → ↓formation PG precursors. - Inhibits formation of thromboxane (TXA) → inhibit aggregation - At higher doses prostacyclin (PFI2) synthesis also inhibited → vasoconstriction (but endothelium can regenerate COX)	Similar mechanism as tirofiban but monoclonal antibody
Absorption	- PO. BA. 50%. - 300mg Loading. 100mg maint.	—
Protein binding	85% protein binding, pKa 3	—
Volume of distribution	Vd 10L	—
Metabolism	- Converted to salicylic acid in GI mucosa and liver - Hepatic conjugation (saturable)	Platelet function typically returns to normal 24-48 hours after infusion ceases
Excretion	- Renal as salicylate	Platelet function typically returns to normal 24-48 hours after infusion ceases
Half-life	- T1/2b 15~20 mins when first order - Dur: 4-6 hrs. (Effect on platelet aggregation will last life of current cohort of platelets (7-10 days)	—
Adverse Effects Toxicity	Bleeding Bronchospasm, Renal toxicity Reye’s Syndrome, GI ulceration Caution with other anticoagulants	Haemorrhage, thrombocytopenia, human antichimeric antibody development, allergic reaction
Class Group	Antiplatelet	Antiplatelet
Introduction	COX inhibitor	GP IIb/IIIA Inhibitor
Legacy Cicm Level	Level 1	Level 3
Main Action	Platelet inhibition	Platelet inhibition